The Use of Antifibrotic Recombinant nAG Protein in a Rat Liver Fibrosis Model
Table 2
Results of the serum levels of various proteins in the three groups.
SERUM LEVEL OF:
Group I
Group II
Group III
(Control)
(CCL4 treatment)
(CCL4/nAG treatment)
N=15
N=15
N=15
Hyaluronic acid
15.133 ± 0.063
29.80 ± 6.145
15.739 ± 3.231
PDGF-AB
18.292 ± 0.023 +
202.839 ± 124.73
58.905 ± 29.198 +
TIMP-1
35.563 ± 0.0299 +
449.25 ± 294.71
161.919 ± 67.518 +
Laminin
257.27 ± 12.91 +
1238.588 ± 622.419
415.34 ± 136.934 +
Procollagen III N-terminal peptide
0.242 ± 0.021 +
0.355 ± 0.050
0.161 ± 0.051+
Collagen Type IV- Alpha-1 chain
2.933 ± 2.193
21.915 ± 9.226
3.08 ± 2.539
There was a significant difference between the control group and the CCL4 treatment group since P < 0.05. There was a significant difference between the CCL4 treatment group and CCL4/nAG treatment group since P < 0.05. +There was a significant difference between the control group and CCL4/nAG treatment group since P < 0.05.
